OLMA
Olema Pharmaceuticals, Inc.Company Information
- Company Name
- Olema Pharmaceuticals, Inc.
- CIK
- CIK0001750284
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- OLMA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- OLMA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-01-08
- Last sale
- 2026-07-24
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 629,179
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 100,548,766
- Shares outstanding
- 104,453,732
- Ownership
- 96.26%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- -9.97%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 49 | 53 | 48 | 35 | 52 | 51 | 139 | 36 | 17 | 34 | 69 | 117 | ||||||
| Marketable Securities Current | 412 | 453 | 457 | 294 | 309 | 342 | 295 | 179 | 222 | 215 | 193 | 159 | ||||||
| Prepaid Expense And Other Assets Current | 9 | 8 | 10 | 5 | 6 | 4 | 4 | 3 | 3 | 3 | 5 | 5 | ||||||
| Assets Current | 470 | 513 | 515 | 334 | 368 | 397 | 438 | 218 | 242 | 252 | 267 | 282 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | ||||||
| Assets | 487 | 531 | 533 | 352 | 382 | 410 | 451 | 230 | 255 | 264 | 277 | 293 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 4 | 9 | 3 | 1 | 0 | 4 | 3 | 4 | 8 | 3 | 2 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Liabilities Current | 51 | 42 | 41 | 37 | 31 | 25 | 36 | 27 | 21 | 18 | 18 | - | ||||||
| Liabilities Current | 53 | 47 | 52 | 42 | 33 | 26 | 42 | 31 | 27 | 26 | 22 | 16 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | ||||||
| Long Term Line Of Credit | 3 | 3 | 3 | 3 | 3 | - | 0 | - | - | - | - | - | ||||||
| Liabilities | 56 | 50 | 55 | 45 | 37 | 26 | 42 | 31 | 27 | 27 | 23 | 18 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,145 | 1,132 | 1,075 | 858 | 854 | 849 | 844 | 600 | 594 | 573 | 559 | 554 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 1 | 1 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -714 | -651 | -598 | -551 | -509 | -465 | -435 | -402 | -367 | -337 | -306 | -279 | ||||||
| Stockholders Equity | 431 | 480 | 479 | 307 | 345 | 383 | 409 | 199 | 227 | 236 | 254 | 275 | ||||||
| Liabilities And Stockholders Equity | 487 | 531 | 533 | 352 | 382 | 410 | 451 | 230 | 255 | 264 | 277 | 293 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | ||||||
| Common Stock Shares Issued | 87 | 87 | 81 | 69 | 69 | 68 | 74 | 57 | 57 | 56 | 55 | 55 | ||||||
| Shares Outstanding | 87 | 87 | 81 | 69 | 69 | 68 | 74 | 57 | 57 | 56 | 55 | 55 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOlema Pharmaceuticals, Inc. (OLMA) — SEC Financial Statements & Analysis
Olema Pharmaceuticals, Inc. (OLMA) is a pharmaceutical preparations company, incorporated in DE. Olema Pharmaceuticals, Inc. trades on Nasdaq as: OLMA. Olema Pharmaceuticals, Inc. (OLMA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Olema Pharmaceuticals, Inc. carries a market cap of $1.31B, a P/E ratio of -6.39x, a P/B ratio of 3.03x, an enterprise value of $1.26B, and an EV/EBITDA multiple of -5.70x. On profitability, it posts a Return on Equity (ROE) of -52.74%, a Return on Assets (ROA) of -47.10%, and a Return on Invested Capital (ROIC) of -65.55%. Per share, it reports EPS of $-1.96, diluted EPS of $-1.96, free cash flow per share of $-1.58, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 43.76% year-over-year and EPS growth of 17.67% year-over-year. On the balance sheet, it maintains a current ratio of 8.86x, a quick ratio of 8.70x, working capital of $416.86M, a debt-to-equity ratio of 0.13x, a debt ratio of 0.12, free cash flow of $-164.96M (TTM), and net debt of $-48.60M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.31B
- P/E TTM
- -6.39x
- EPS TTM
- $-1.96
- P/B TTM
- 3.03x
- ROE TTM
- -52.74%
- ROA TTM
- -47.10%
- Debt To Equity
- 0.13x
- Free Cash Flow TTM
- $-164.96M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Olema Pharmaceuticals, Inc. in?
Olema Pharmaceuticals, Inc. (OLMA) operates in the Pharmaceutical Preparations industry.
What exchange does OLMA trade on?
Olema Pharmaceuticals, Inc. (OLMA) trades on the Nasdaq.
Where is Olema Pharmaceuticals, Inc. incorporated?
Olema Pharmaceuticals, Inc. is incorporated in DE.
When was Olema Pharmaceuticals, Inc. (OLMA)'s most recent SEC filing?
Olema Pharmaceuticals, Inc. (OLMA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is OLMA's market cap?
Olema Pharmaceuticals, Inc. (OLMA) has a market capitalization of $1.31B as of 2026-06-30.
What is OLMA's EPS (earnings per share)?
Olema Pharmaceuticals, Inc. (OLMA)'s trailing twelve month EPS is $-1.96 as of 2026-06-30.
What is OLMA's ROE (return on equity)?
Olema Pharmaceuticals, Inc. (OLMA)'s trailing twelve month Return on Equity (ROE) is -52.74% as of 2026-06-30.
What is OLMA's ROA (return on assets)?
Olema Pharmaceuticals, Inc. (OLMA)'s trailing twelve month Return on Assets (ROA) is -47.10% as of 2026-06-30.
What is OLMA's ROIC (return on invested capital)?
Olema Pharmaceuticals, Inc. (OLMA)'s trailing twelve month Return on Invested Capital (ROIC) is -65.55% as of 2026-06-30.
What is OLMA's EV/EBITDA?
Olema Pharmaceuticals, Inc. (OLMA)'s trailing twelve month EV/EBITDA is -5.70x as of 2026-06-30.